| Name | Eledon Pharmaceuticals, Inc. |
|---|---|
| CIK | 0001404281 |
| Tickers | ELDN |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 000000000 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 949-238-8090 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
No Financialist filing articles yet for this CIK.
617 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000921895-26-003175 | 005-88334 | 261560873 | 34 | 30378 | |||
| 2026-11-12 | 10-Q | 10-Q | 0001193125-26-458564 | 001-36620 | 261547588 | 34 | 11454714 | 1 | 1 | |
| 2026-11-12 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-458378 | 001-36620 | 261547007 | 34 | 452079 | 1 | 1 |
| 2026-10-30 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0002100119-26-001561 | 005-88334 | 261505524 | 34 | 7744 | |||
| 2026-09-04 | S-8 | S-8 | 0001193125-26-383824 | 333-298779 | 261362825 | 33 | 255414 | 1 | 1 | |
| 2026-08-13 | 10-Q | 10-Q | 0001193125-26-349314 | 001-36620 | 261274045 | 34 | 10797542 | 1 | 1 | |
| 2026-08-13 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-349170 | 001-36620 | 261273353 | 34 | 430027 | 1 | 1 |
| 2026-08-04 | 4 | 4 | 0001193125-26-333136 | 6603 | ||||||
| 2026-08-04 | 4 | 4 | 0001193125-26-333133 | 6556 | ||||||
| 2026-07-31 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0002100119-26-001370 | 005-88334 | 261225989 | 34 | 7642 | |||
| 2026-06-22 | 8-K | 8-K | 5.03,5.07,9.01 | 0001193125-26-277653 | 001-36620 | 261107927 | 34 | 193890 | 1 | 1 |
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000921895-26-001390 | 005-88334 | 26987231 | 34 | 30238 | |||
| 2026-05-13 | 10-Q | 10-Q | 0001193125-26-221702 | 001-36620 | 26973650 | 34 | 9358189 | 1 | 1 | |
| 2026-05-13 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-221658 | 001-36620 | 26973460 | 34 | 378332 | 1 | 1 |
| 2026-05-11 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-001576 | 333-295498 | 26965525 | 33 | 1966 | ||
| 2026-05-07 | CORRESP | filename1.htm | 0001193125-26-212858 | 6554 | ||||||
| 2026-05-07 | UPLOAD | filename1.pdf | 0000000000-26-004691 | 333-295498 | 150220 | |||||
| 2026-05-01 | S-3 | S-3 | 0001193125-26-201426 | 333-295498 | 26932546 | 33 | 1317801 | 1 | 1 | |
| 2026-04-30 | DEFA14A | DEFA14A | 0001193125-26-197775 | 001-36620 | 26926999 | 34 | 3134224 | 1 | 1 | |
| 2026-04-30 | ARS | ARS | 0001193125-26-197765 | 001-36620 | 26926947 | 34 | 2927294 | |||
| 2026-04-30 | DEF 14A | DEF 14A | 0001193125-26-197732 | 001-36620 | 26926777 | 34 | 6711501 | 1 | 1 | |
| 2026-04-27 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0002012383-26-001685 | 005-88334 | 26901058 | 34 | 11021 | |||
| 2026-04-21 | PRE 14A | PRE 14A | 0001193125-26-164367 | 001-36620 | 26876229 | 34 | 6146754 | 1 | 1 | |
| 2026-03-26 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000102909-26-001125 | 005-88334 | 26799884 | 34 | 7382 | |||
| 2026-03-19 | 10-K | 10-K | 0001193125-26-116164 | 001-36620 | 26775107 | 34 | 17567906 | 1 | 1 | |
| 2026-03-19 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-116154 | 001-36620 | 26775071 | 34 | 371361 | 1 | 1 |
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001346824-26-000041 | 005-88334 | 26642052 | 34 | 12887 | |||
| 2026-02-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-26-015219 | 005-88334 | 26633011 | 34 | 19628 | |||
| 2026-01-21 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002012383-26-000664 | 005-88334 | 26545828 | 34 | 10984 | |||
| 2026-01-16 | 4 | 4 | 0001193125-26-015489 | 6978 | ||||||
| 2026-01-16 | 4 | 4 | 0001193125-26-015488 | 6969 | ||||||
| 2026-01-16 | 4 | 4 | 0001193125-26-015487 | 6975 | ||||||
| 2026-01-16 | 4 | 4 | 0001193125-26-015486 | 6972 | ||||||
| 2026-01-16 | 4 | 4 | 0001193125-26-015485 | 6960 | ||||||
| 2026-01-16 | 4 | 4 | 0001193125-26-015484 | 6990 | ||||||
| 2026-01-02 | 8-K | 8-K | 3.02,9.01 | 0001193125-26-000968 | 001-36620 | 26502782 | 34 | 311942 | 1 | 1 |
| 2025-11-24 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-115374 | 005-88334 | 251512481 | 34 | 27985 | |||
| 2025-11-14 | 8-K | 8-K | 2.02,9.01 | 0001193125-25-283294 | 001-36620 | 251488142 | 34 | 516589 | 1 | 1 |
| 2025-11-14 | 10-Q | 10-Q | 0001193125-25-283275 | 001-36620 | 251488034 | 34 | 12648794 | 1 | 1 | |
| 2025-11-13 | 8-K | 8-K | 1.01,9.01 | 0001193125-25-278392 | 001-36620 | 251475081 | 34 | 618338 | 1 | 1 |
| 2025-11-13 | 424B5 | 424B5 | 0001193125-25-278390 | 333-282260 | 251475073 | 33 | 531903 | |||
| 2025-11-12 | 424B5 | 424B5 | 0001193125-25-275606 | 333-282260 | 251468163 | 33 | 532971 | |||
| 2025-11-07 | 8-K | 8-K | 2.02,7.01,9.01 | 0001193125-25-270286 | 001-36620 | 251459958 | 34 | 236972 | 1 | 1 |
| 2025-08-14 | 10-Q | 10-Q | 0001193125-25-180906 | 001-36620 | 251220916 | 34 | 11702880 | 1 | 1 | |
| 2025-08-14 | 10-Q/A | 10-Q/A | 0001193125-25-180904 | 001-36620 | 251220871 | 34 | 11107020 | 1 | 1 | |
| 2025-08-14 | 10-K/A | 10-K/A | 0001193125-25-180865 | 001-36620 | 251220372 | 34 | 19949453 | 1 | 1 | |
| 2025-08-14 | 8-K | 8-K | 2.02,4.02,9.01 | 0001193125-25-180820 | 001-36620 | 251219909 | 34 | 474473 | 1 | 1 |
| 2025-08-06 | 8-K | 8-K | 7.01,9.01 | 0000950170-25-103975 | 001-36620 | 251189421 | 34 | 217234 | 1 | 1 |
| 2025-07-29 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000932471-25-000874 | 005-88334 | 251159901 | 34 | 6381 | |||
| 2025-07-17 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0002052113-25-003025 | 005-88334 | 251132191 | 34 | 10933 | |||
| 2025-06-12 | 8-K | 8-K | 5.03,5.07,9.01 | 0000950170-25-085588 | 001-36620 | 251043919 | 34 | 221016 | 1 | 1 |
| 2025-05-14 | 10-Q | 10-Q | 0000950170-25-071582 | 001-36620 | 25946862 | 34 | 9570918 | 1 | 1 | |
| 2025-05-14 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-071370 | 001-36620 | 25945351 | 34 | 395028 | 1 | 1 |
| 2025-04-29 | ARS | ARS | 0000950170-25-060324 | 001-36620 | 25889223 | 34 | 3139084 | |||
| 2025-04-29 | DEFA14A | DEFA14A | 0000950170-25-060316 | 001-36620 | 25889066 | 34 | 1148428 | |||
| 2025-04-29 | DEF 14A | DEF 14A | 0000950170-25-060299 | 001-36620 | 25888950 | 34 | 10594200 | 1 | 1 | |
| 2025-04-14 | PRE 14A | PRE 14A | 0000950170-25-053771 | 001-36620 | 25836669 | 34 | 10516129 | 1 | 1 | |
| 2025-04-14 | 8-K/A | 8-K/A | 4.01,9.01 | 0000950170-25-053765 | 001-36620 | 25836621 | 34 | 169795 | 1 | 1 |
| 2025-04-07 | 8-K | 8-K | 4.01,9.01 | 0000950170-25-051663 | 001-36620 | 25818867 | 34 | 204542 | 1 | 1 |
| 2025-03-20 | 10-K | 10-K | 0000950170-25-042754 | 001-36620 | 25757334 | 34 | 19379830 | 1 | 1 | |
| 2025-03-20 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-042644 | 001-36620 | 25756440 | 34 | 387791 | 1 | 1 |
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001172661-25-001292 | 005-88334 | 25631296 | 34 | 10825 | |||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001415889-25-003986 | 005-88334 | 25625048 | 34 | 58126 | |||
| 2025-01-13 | 4 | 4 | 0000950170-25-004925 | 7758 | ||||||
| 2025-01-13 | 4 | 4 | 0000950170-25-004924 | 7761 | ||||||
| 2025-01-13 | 4 | 4 | 0000950170-25-004923 | 8575 | ||||||
| 2025-01-13 | 4 | 4 | 0000950170-25-004918 | 8600 | ||||||
| 2025-01-13 | 4 | 4 | 0000950170-25-004922 | 7750 | ||||||
| 2025-01-13 | 4 | 4 | 0000950170-25-004921 | 8584 | ||||||
| 2025-01-13 | 4 | 4 | 0000950170-25-004916 | 8557 | ||||||
| 2025-01-13 | 4 | 4 | 0000950170-25-004915 | 7733 | ||||||
| 2025-01-13 | 4 | 4 | 0000950170-25-004920 | 7721 | ||||||
| 2025-01-13 | 4 | 4 | 0000950170-25-004914 | 7764 | ||||||
| 2024-12-20 | 8-K | 8-K | 5.02,9.01 | 0000950170-24-138782 | 001-36620 | 241565154 | 34 | 151540 | 1 | 1 |
| 2024-11-22 | 4 | 4 | 0000950170-24-130275 | 6043 | ||||||
| 2024-11-22 | 4 | 4 | 0000950170-24-130278 | 6086 | ||||||
| 2024-11-22 | 4 | 4 | 0000950170-24-130273 | 6059 | ||||||
| 2024-11-22 | 4 | 4 | 0000950170-24-130272 | 6082 | ||||||
| 2024-11-14 | SC 13G/A | armistice-eldn093024a1.htm | 0001172661-24-005294 | 005-88334 | 241463758 | 34 | 90825 | |||
| 2024-11-12 | 10-Q | 10-Q | 0000950170-24-125622 | 001-36620 | 241449584 | 34 | 9789923 | 1 | 1 | |
| 2024-11-12 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-125340 | 001-36620 | 241447937 | 34 | 372931 | 1 | 1 |
| 2024-11-05 | SC 13G | SC 13G | 0001104659-24-114322 | 005-88334 | 241427725 | 34 | 77419 | |||
| 2024-11-05 | SC 13G | SC 13G | 0001193125-24-251059 | 005-88334 | 241426359 | 34 | 325167 | |||
| 2024-10-31 | 4 | OWNERSHIP DOCUMENT | 0000921895-24-002408 | 60796 | ||||||
| 2024-10-31 | SC 13G/A | AMENDMENT NO. 10 TO SCHEDULE 13G | 0000921895-24-002407 | 005-88334 | 241416402 | 34 | 289991 | |||
| 2024-10-31 | SC 13G/A | AMENDMENT NO. 9 TO SCHEDULE 13G | 0000921895-24-002406 | 005-88334 | 241416398 | 34 | 290096 | |||
| 2024-10-30 | 424B5 | 424B5 | 0001193125-24-246779 | 333-282260 | 241407342 | 33 | 459301 | |||
| 2024-10-30 | 424B5 | 424B5 | 0001193125-24-246773 | 333-282260 | 241407288 | 33 | 459720 | |||
| 2024-10-30 | 8-K | 8-K | 1.01,7.01,9.01 | 0000950170-24-118497 | 001-36620 | 241407163 | 34 | 956749 | 1 | 1 |
| 2024-10-29 | 8-K | 8-K | 7.01,9.01 | 0000950170-24-117946 | 001-36620 | 241402726 | 34 | 199518 | 1 | 1 |
| 2024-10-02 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2024-10-02 10:00:00 | 9999999995-24-003069 | 333-282260 | 241349720 | 33 | 1974 | ||
| 2024-10-01 | 8-K | 8-K | 3.02 | 0000950170-24-110857 | 001-36620 | 241343695 | 34 | 147520 | 1 | 1 |
| 2024-09-30 | CORRESP | filename1.htm | 0000950170-24-110267 | 10829 | ||||||
| 2024-09-26 | UPLOAD | filename1.pdf | 0000000000-24-010968 | 333-282260 | 40335 | |||||
| 2024-09-20 | 8-K | 8-K | 1.01,9.01 | 0000950170-24-108465 | 001-36620 | 241314018 | 34 | 157343 | 1 | 1 |
| 2024-09-20 | S-3 | S-3 | 0001193125-24-222880 | 333-282260 | 241313600 | 33 | 1334902 | |||
| 2024-08-19 | 10-Q | 10-Q | 0000950170-24-098590 | 001-36620 | 241221145 | 34 | 8712439 | 1 | 1 | |
| 2024-08-19 | 10-Q/A | 10-Q/A | 0000950170-24-098582 | 001-36620 | 241221098 | 34 | 7818366 | 1 | 1 | |
| 2024-08-19 | 10-K/A | 10-K/A | 0000950170-24-098575 | 001-36620 | 241221021 | 34 | 15985409 | 1 | 1 | |
| 2024-08-14 | 8-K | 8-K | 2.02,4.02,9.01 | 0000950170-24-097206 | 001-36620 | 241209526 | 34 | 209941 | 1 | 1 |
| 2024-08-14 | NT 10-Q | NT 10-Q | 0000950170-24-097200 | 001-36620 | 241209482 | 34 | 96801 | |||
| 2024-07-12 | 8-K | 8-K | 4.01,9.01 | 0000950170-24-083220 | 001-36620 | 241114832 | 34 | 165301 | 1 | 1 |
| 2024-07-10 | 8-K | 8-K | 3.02 | 0000950170-24-082739 | 001-36620 | 241110412 | 34 | 147228 | 1 | 1 |
| 2024-07-10 | 8-K | 8-K | 5.02,5.07,8.01,9.01 | 0000950170-24-082730 | 001-36620 | 241110364 | 34 | 363905 | 1 | 1 |
| 2024-06-14 | 4 | 4 | 0000950170-24-073772 | 6068 | ||||||
| 2024-06-14 | 4 | 4 | 0000950170-24-073771 | 6034 | ||||||
| 2024-06-14 | 4 | 4 | 0000950170-24-073770 | 6051 | ||||||
| 2024-06-14 | 4 | 4 | 0000950170-24-073767 | 6076 | ||||||
| 2024-06-06 | 424B3 | 424B3 | 0001193125-24-156034 | 333-279711 | 241024937 | 33 | 178708 | |||
| 2024-06-05 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2024-06-05 10:00:00 | 9999999995-24-001759 | 333-279711 | 241023757 | 33 | 1974 | ||
| 2024-06-03 | CORRESP | filename1.htm | 0000950170-24-067759 | 10489 | ||||||
| 2024-05-30 | UPLOAD | filename1.pdf | 0000000000-24-006252 | 333-279711 | 40525 | |||||
| 2024-05-30 | ARS | ARS | 0000950170-24-066631 | 001-36620 | 241005705 | 34 | 2912105 | |||
| 2024-05-30 | DEFA14A | DEFA14A | 0000950170-24-066587 | 001-36620 | 241005452 | 34 | 1701110 | |||
| 2024-05-30 | DEF 14A | DEF 14A | 0000950170-24-066564 | 001-36620 | 241005175 | 34 | 6476954 | 1 | 1 | |
| 2024-05-24 | S-3 | FORM S-3 | 0001193125-24-147011 | 333-279711 | 24984155 | 33 | 271625 | |||
| 2024-05-23 | D | xslFormDX01/primary_doc.xml | 06b | 0001404281-24-000002 | 021-514042 | 24974914 | 33 | 17171 | ||
| 2024-05-15 | 10-Q | 10-Q | 0000950170-24-060025 | 001-36620 | 24947091 | 34 | 6325713 | 1 | 1 | |
| 2024-05-13 | 4 | OWNERSHIP DOCUMENT | 0000921895-24-001131 | 70831 | ||||||
| 2024-05-13 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-058706 | 001-36620 | 24939556 | 34 | 329236 | 1 | 1 |
| 2024-05-07 | 8-K | 8-K | 1.01,3.02,7.01,9.01 | 0000950170-24-053934 | 001-36620 | 24919593 | 34 | 1236708 | 1 | 1 |
| 2024-04-26 | 10-K/A | 10-K/A | 0000950170-24-049277 | 001-36620 | 24884939 | 34 | 2792371 | 1 | 1 | |
| 2024-03-28 | 10-K | 10-K | 0000950170-24-038091 | 001-36620 | 24799595 | 34 | 12870749 | 1 | 1 | |
| 2024-03-28 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-038008 | 001-36620 | 24798674 | 34 | 328171 | 1 | 1 |
| 2024-02-14 | SC 13G | armistice-eldn123123.htm | 0001172661-24-001341 | 005-88334 | 24636912 | 34 | 90774 | |||
| 2024-02-14 | SC 13G/A | AMENDMENT NO. 3 | 0000929638-24-000642 | 005-88334 | 24636496 | 34 | 84358 | |||
| 2024-02-14 | SC 13G/A | AMENDMENT NO. 8 TO SCHEDULE 13G | 0000921895-24-000452 | 005-88334 | 24633467 | 34 | 288628 | |||
| 2023-11-09 | 10-Q | 10-Q | 0000950170-23-062203 | 001-36620 | 231393545 | 34 | 7118421 | 1 | 1 | |
| 2023-11-09 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-062007 | 001-36620 | 231392253 | 34 | 386752 | 1 | 1 |
| 2023-11-02 | 8-K | 8-K | 7.01,9.01 | 0000950170-23-058279 | 001-36620 | 231372868 | 34 | 8431073 | 1 | 1 |
| 2023-10-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-051460 | 5584 | ||||||
| 2023-10-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-051456 | 5629 | ||||||
| 2023-10-02 | 3 | FORM 3 SUBMISSION | 0001209191-23-051161 | 7114 | ||||||
| 2023-10-02 | 3 | FORM 3 SUBMISSION | 0001209191-23-051131 | 7168 | ||||||
| 2023-10-02 | 8-K | 8-K | 5.02 | 0000950170-23-050925 | 001-36620 | 231297725 | 34 | 161379 | 1 | 1 |
| 2023-09-21 | 8-K | 8-K | 5.02,9.01 | 0000950170-23-049046 | 001-36620 | 231267501 | 34 | 339915 | 1 | 1 |
| 2023-09-13 | 8-K | 8-K | 5.02 | 0000950170-23-047951 | 001-36620 | 231253183 | 34 | 161325 | 1 | 1 |
| 2023-08-11 | S-8 | S-8 | 0000950170-23-041515 | 333-273900 | 231161023 | 33 | 300233 | |||
| 2023-08-10 | 10-Q | 10-Q | 0000950170-23-041456 | 001-36620 | 231160480 | 34 | 7829413 | 1 | 1 | |
| 2023-08-10 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-040949 | 001-36620 | 231157146 | 34 | 422441 | 1 | 1 |
| 2023-06-22 | 8-K | 8-K | 5.02,5.07,9.01 | 0000950170-23-029259 | 001-36620 | 231031242 | 34 | 405033 | 1 | 1 |
| 2023-06-08 | 424B3 | 424B3 | 0001193125-23-163490 | 333-272052 | 231001882 | 33 | 217984 | |||
| 2023-06-02 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2023-06-02 10:00:00 | 9999999995-23-001622 | 333-272052 | 23991107 | 33 | 1924 | ||
| 2023-05-31 | CORRESP | filename1.htm | 0001193125-23-157490 | 6222 | ||||||
| 2023-05-24 | UPLOAD | filename1.pdf | 0000000000-23-005538 | 40491 | ||||||
| 2023-05-22 | D | xslFormDX01/primary_doc.xml | 06b | 0001404281-23-000002 | 021-482292 | 23943612 | 33 | 16527 | ||
| 2023-05-18 | S-3 | S-3 | 0001193125-23-148292 | 333-272052 | 23937041 | 33 | 311980 | |||
| 2023-05-11 | 10-Q | 10-Q | 0000950170-23-021372 | 001-36620 | 23912102 | 34 | 5599500 | 1 | 1 | |
| 2023-05-11 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-021198 | 001-36620 | 23910852 | 34 | 388062 | 1 | 1 |
| 2023-05-09 | 4 | OWNERSHIP DOCUMENT | 0000921895-23-001098 | 67701 | ||||||
| 2023-05-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-026734 | 5743 | ||||||
| 2023-05-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-026733 | 5717 | ||||||
| 2023-05-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-026732 | 5729 | ||||||
| 2023-05-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-026731 | 5569 | ||||||
| 2023-05-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-026730 | 5737 | ||||||
| 2023-05-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-026728 | 5605 | ||||||
| 2023-05-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-026727 | 5609 | ||||||
| 2023-05-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-026725 | 5634 | ||||||
| 2023-05-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-026724 | 5581 | ||||||
| 2023-05-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-026721 | 5605 | ||||||
| 2023-05-01 | DEF 14A | DEF 14A | 0000950170-23-016306 | 001-36620 | 23874603 | 34 | 8244620 | 1 | 1 | |
| 2023-05-01 | ARS | ARS | 0000950170-23-016305 | 001-36620 | 23874596 | 34 | 1653417 | |||
| 2023-05-01 | DEFA14A | DEFA14A | 0000950170-23-016299 | 001-36620 | 23874539 | 34 | 1397742 | |||
| 2023-05-01 | 8-K | 8-K | 1.01,3.02,5.02,7.01,9.01 | 0000950170-23-016017 | 001-36620 | 23870003 | 34 | 2253960 | 1 | 1 |
| 2023-03-30 | 10-K | 10-K | 0000950170-23-011011 | 001-36620 | 23781555 | 34 | 11641125 | 1 | 1 | |
| 2023-03-30 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-010924 | 001-36620 | 23780605 | 34 | 798249 | 1 | 1 |
| 2023-02-14 | SC 13G/A | schedule13ga.htm | 0000929638-23-000549 | 005-88334 | 23627627 | 34 | 86213 | |||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006364 | 5695 | ||||||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006359 | 5502 | ||||||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006355 | 5542 | ||||||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006351 | 5585 | ||||||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006345 | 5514 | ||||||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006339 | 5537 | ||||||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006329 | 5539 | ||||||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006324 | 8499 | ||||||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006309 | 5724 | ||||||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006300 | 5715 | ||||||
| 2023-01-09 | 8-K | 8-K | 7.01,9.01 | 0000950170-23-000465 | 001-36620 | 23516786 | 34 | 16438191 | 1 | 1 |
| 2022-11-23 | 4 | FORM 4 SUBMISSION | 0001209191-22-058608 | 4964 | ||||||
| 2022-11-14 | 10-Q | 10-Q | 0000950170-22-025007 | 001-36620 | 221387497 | 34 | 6149688 | 1 | 1 | |
| 2022-11-14 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-024980 | 001-36620 | 221385062 | 34 | 950960 | 1 | 1 |
| 2022-08-11 | 10-Q | 10-Q | 0000950170-22-016935 | 001-36620 | 221156800 | 34 | 6909147 | 1 | 1 | |
| 2022-08-11 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-016850 | 001-36620 | 221155676 | 34 | 443478 | 1 | 1 |
| 2022-06-23 | 8-K | 8-K | 5.07 | 0000950170-22-011978 | 001-36620 | 221033141 | 34 | 186495 | 1 | 1 |
| 2022-05-31 | 8-K | 8-K | 7.01,8.01,9.01 | 0000950170-22-010890 | 001-36620 | 22980368 | 34 | 2288053 | 1 | 1 |
| 2022-05-12 | 10-Q | 10-Q | 0001564590-22-019921 | 001-36620 | 22918803 | 34 | 4858866 | 1 | 1 | |
| 2022-05-12 | 8-K | 8-K 2022 Q1 | 2.02,9.01 | 0001564590-22-019851 | 001-36620 | 22917805 | 34 | 392293 | 1 | 1 |
| 2022-04-28 | DEFA14A | DEFA14A | 0001564590-22-016521 | 001-36620 | 22868163 | 34 | 620278 | |||
| 2022-04-28 | DEF 14A | DEF 14A | 0001564590-22-016509 | 001-36620 | 22867854 | 34 | 1650976 | |||
| 2022-03-24 | 10-K | 10-K | 0001564590-22-011698 | 001-36620 | 22767333 | 34 | 13156476 | 1 | 1 | |
| 2022-03-24 | 8-K | 8-K | 2.02,9.01 | 0001564590-22-011680 | 001-36620 | 22766542 | 34 | 399169 | 1 | 1 |
| 2022-02-14 | SC 13G/A | schedule13g.htm | 0000929638-22-000470 | 005-88334 | 22630046 | 34 | 87077 | |||
| 2022-02-11 | SC 13G/A | ELEDON PHARMACEUTICALS, INC. | 0000902664-22-001492 | 005-88334 | 22616698 | 34 | 50677 | |||
| 2022-02-10 | SC 13G/A | ELEDON PHARMACEUTICALS, INC. | 0000902664-22-001334 | 005-88334 | 22611359 | 34 | 106907 | |||
| 2022-02-09 | SC 13G/A | filing.txt | 0000315066-22-000854 | 005-88334 | 22604179 | 34 | 8618 | |||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006492 | 5707 | ||||||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006489 | 5724 | ||||||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006486 | 5695 | ||||||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006485 | 5502 | ||||||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006480 | 5543 | ||||||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006476 | 5585 | ||||||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006471 | 5514 | ||||||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006466 | 5537 | ||||||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006464 | 5539 | ||||||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006446 | 5715 | ||||||
| 2022-01-31 | 3 | xslF345X02/form307422010_01312022.xml | 0001193805-22-000135 | 45152 | ||||||
| 2022-01-28 | SC 13G/A | AMENDMENT NO. 7 TO SCHEDULE 13G | 0000921895-22-000268 | 005-88334 | 22569403 | 34 | 284841 | |||
| 2022-01-26 | SC 13G/A | eledonpharm13g.htm | 0000935836-22-000036 | 005-88334 | 22558340 | 34 | 59872 | |||
| 2022-01-13 | 8-K | 8-K FOR BVF COMMON SHARE EXCHANGE AGREEMENT | 3.02,9.01 | 0001564590-22-001203 | 001-36620 | 22529052 | 34 | 228003 | 1 | 1 |
| 2022-01-11 | SC 13G/A | sc13ga607422eldn_01102022.htm | 0000921895-22-000117 | 005-88334 | 22522237 | 34 | 284789 | |||
| 2022-01-11 | SC 13G/A | AMENDMENT NO. 5 TO THE SCHEDULE 13G | 0000921895-22-000116 | 005-88334 | 22522227 | 34 | 284625 | |||
| 2021-12-21 | 4 | FORM 4 SUBMISSION | 0000899243-21-049171 | 4966 | ||||||
| 2021-11-12 | 10-Q | 10-Q | 0001564590-21-056417 | 001-36620 | 211399329 | 34 | 6992757 | 1 | 1 | |
| 2021-11-12 | 8-K | 8-K FOR Q3'21 EARNINGS RELEASE | 2.02,9.01 | 0001564590-21-056413 | 001-36620 | 211399293 | 34 | 460665 | 1 | 1 |
| 2021-09-09 | SC 13G/A | eledonpharm13g.htm | 0000935836-21-000506 | 005-88334 | 211243978 | 34 | 60843 | |||
| 2021-08-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-052519 | 5348 | ||||||
| 2021-08-12 | 10-Q | 10-Q | 0001564590-21-044038 | 001-36620 | 211168526 | 34 | 6307282 | 1 | 1 | |
| 2021-08-12 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-043944 | 001-36620 | 211167367 | 34 | 462747 | 1 | 1 |
| 2021-08-02 | 8-K | 8-K | 5.02 | 0001564590-21-039644 | 001-36620 | 211134872 | 34 | 169367 | 1 | 1 |
| 2021-07-09 | 3 | FORM 3 SUBMISSION | 0000899243-21-028049 | 8250 | ||||||
| 2021-07-02 | 8-K | 8-K | 5.02 | 0001564590-21-035584 | 001-36620 | 211068078 | 34 | 170929 | 1 | 1 |
| 2021-06-16 | 8-K | 8-K | 5.07 | 0001564590-21-033187 | 001-36620 | 211021414 | 34 | 192620 | 1 | 1 |
| 2021-06-14 | 4 | FORM 4 SUBMISSION | 0000899243-21-023640 | 5402 | ||||||
| 2021-06-10 | 4 | FORM 4 SUBMISSION | 0000899243-21-022998 | 5002 | ||||||
| 2021-05-21 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2021-05-21 17:30:00 | 9999999995-21-002058 | 333-254890 | 21950967 | 33 | 1924 | ||
| 2021-05-21 | S-3/A | S-3/A | 0001193125-21-169408 | 333-254890 | 21950048 | 33 | 59479 | |||
| 2021-05-18 | CORRESP | filename1.htm | 0001193125-21-165620 | 6766 | ||||||
| 2021-05-14 | 10-Q | 10-Q | 0001564590-21-027695 | 001-36620 | 21921166 | 34 | 4975598 | 1 | ||
| 2021-05-13 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-027581 | 001-36620 | 21919975 | 34 | 248996 | ||
| 2021-05-04 | 4 | FORM 4 SUBMISSION | 0000899243-21-018105 | 5799 | ||||||
| 2021-04-29 | DEFA14A | DEFA14A | 0001564590-21-022019 | 001-36620 | 21871380 | 34 | 228549 | |||
| 2021-04-29 | DEF 14A | DEF 14A | 0001564590-21-022013 | 001-36620 | 21871293 | 34 | 1221613 | |||
| 2021-04-27 | 8-K | 8-K | 8.01,9.01 | 0001564590-21-020624 | 001-36620 | 21855501 | 34 | 76615 | ||
| 2021-04-20 | 3 | FORM 3 SUBMISSION | 0000899243-21-016352 | 7073 | ||||||
| 2021-04-12 | S-8 | S-8 | 0001193125-21-111836 | 333-255173 | 21819139 | 33 | 187944 | |||
| 2021-04-05 | UPLOAD | filename1.pdf | 0000000000-21-004037 | 40424 | ||||||
| 2021-03-31 | S-3 | S-3 | 0001193125-21-101240 | 333-254890 | 21789759 | 33 | 1344941 | |||
| 2021-03-31 | 10-K | 10-K | 0001564590-21-016828 | 001-36620 | 21789384 | 34 | 12006974 | 1 | ||
| 2021-03-19 | 3 | FORM 3 SUBMISSION | 0000899243-21-012708 | 8415 | ||||||
| 2021-03-15 | 8-K | 8-K | 5.02 | 0001564590-21-013094 | 001-36620 | 21740990 | 34 | 36543 | ||
| 2021-02-16 | SC 13G | woodline-eldn123120.htm | 0001172661-21-000765 | 005-88334 | 21639519 | 34 | 54298 | |||
| 2021-02-16 | SC 13G/A | AMENDMENT NO. 4 TO THE SCHEDULE 13G | 0000921895-21-000474 | 005-88334 | 21638713 | 34 | 303212 | |||
| 2021-02-16 | SC 13G/A | eledon13ga2-021621.htm | 0001013594-21-000165 | 005-88334 | 21636906 | 34 | 74372 | |||
| 2021-02-08 | SC 13G | filing.txt | 0000315066-21-001179 | 005-88334 | 21599724 | 34 | 8547 | |||
| 2021-01-07 | 8-K | 8-K | 3.02,9.01 | 0001193125-21-003750 | 001-36620 | 21513015 | 34 | 306709 | 1 | 1 |
| 2021-01-05 | SC 13D/A | AMENDMENT NO. 8 | 0000947871-21-000013 | 005-88334 | 21506311 | 34 | 78498 | |||
| 2021-01-05 | 8-K | FORM 8-K | 5.03,8.01,9.01 | 0001104659-21-000921 | 001-36620 | 21505527 | 34 | 414840 | 1 | 1 |
| 2021-01-04 | SC 13G | ELEDON PHARMACEUTICALS, INC. | 0000902664-21-000010 | 005-88334 | 21501823 | 34 | 108927 | |||
| 2021-01-04 | SC 13G | schedule13g.htm | 0000929638-21-000023 | 005-88334 | 21501758 | 34 | 90373 | |||
| 2020-12-30 | SC 13G/A | AMENDMENT NO. 3 TO THE SCHEDULE 13G | 0000921895-20-003303 | 005-88334 | 201426832 | 34 | 292645 | |||
| 2020-12-28 | SC 13G/A | AMENDMENT NO. 2 TO THE SCHEDULE 13G | 0000921895-20-003279 | 005-88334 | 201419103 | 34 | 293179 | |||
| 2020-12-28 | 4 | OWNERSHIP DOCUMENT | 0000921895-20-003278 | 59364 | ||||||
| 2020-12-22 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2020-12-22 16:00:00 | 9999999995-20-003635 | 333-251305 | 201409662 | 33 | 1816 | ||
| 2020-12-22 | 424B2 | 424B2 | 0001193125-20-324618 | 333-251305 | 201408649 | 33 | 154998 | |||
| 2020-12-22 | 8-K | 8-K | 5.07 | 0001193125-20-323914 | 001-36620 | 201406096 | 34 | 181591 | 1 | 1 |
| 2020-12-17 | CORRESP | filename1.htm | 0001193125-20-320049 | 6095 | ||||||
| 2020-12-16 | UPLOAD | filename1.pdf | 0000000000-20-012123 | 40290 | ||||||
| 2020-12-14 | 3 | FORM 3 SUBMISSION | 0000899243-20-033730 | 8094 | ||||||
| 2020-12-11 | S-3 | S-3 | 0001193125-20-315955 | 333-251305 | 201383972 | 33 | 228910 | |||
| 2020-12-10 | 8-K | 8-K | 5.03 | 0001564590-20-056746 | 001-36620 | 201381288 | 34 | 35991 | ||
| 2020-12-10 | DEFA14A | DEFA14A | 0001193125-20-314322 | 001-36620 | 201379356 | 34 | 33672 | |||
| 2020-12-04 | 4 | xslF345X03/ownership.xml | 0000947871-20-000933 | 8112 | ||||||
| 2020-12-04 | SC 13D/A | AMENDMENT NO. 7 | 0000947871-20-000932 | 005-88334 | 201370627 | 34 | 81053 | |||
| 2020-11-20 | UPLOAD | filename1.pdf | 0000000000-20-011154 | 39820 | ||||||
| 2020-11-20 | SC 13D/A | AMENDMENT NO. 6 | 0000947871-20-000897 | 005-88334 | 201333006 | 34 | 79932 | |||
| 2020-11-20 | 8-K | 8-K | 5.03,9.01 | 0001564590-20-054793 | 001-36620 | 201332740 | 34 | 262356 | ||
| 2020-11-20 | 8-K/A | 8-K AMENDMENT NO 1 | 9.01 | 0001193125-20-298749 | 001-36620 | 201330530 | 34 | 27811 | ||
| 2020-11-20 | DEF 14A | DEF 14A | 0001193125-20-298745 | 001-36620 | 201330525 | 34 | 2091570 | |||
| 2020-11-16 | 10-Q | 10-Q | 0001564590-20-054210 | 001-36620 | 201318143 | 34 | 7256778 | 1 | ||
| 2020-11-13 | CORRESP | filename1.htm | 0001193125-20-293186 | 33098 | ||||||
| 2020-11-13 | PRER14A | PRER14A | 0001193125-20-293174 | 001-36620 | 201312413 | 34 | 2029483 | |||
| 2020-11-09 | SC 13G | nvus13g.htm | 0000935836-20-000603 | 005-88334 | 201296852 | 34 | 61516 | |||
| 2020-11-09 | UPLOAD | filename1.pdf | 0000000000-20-010686 | 45556 | ||||||
| 2020-11-06 | 4 | FORM 4 | 0001567619-20-018886 | 19082 | ||||||
| 2020-11-06 | 3 | FORM 3 | 0001567619-20-018885 | 6762 | ||||||
| 2020-10-23 | PRE 14A | PRE 14A | 0001193125-20-275595 | 001-36620 | 201258497 | 34 | 1984224 | |||
| 2020-10-14 | SC 13D/A | AMENDMENT NO. 5 | 0000947871-20-000795 | 005-88334 | 201237893 | 34 | 79625 | |||
| 2020-10-06 | 8-K | 8-K | 5.03,9.01 | 0001193125-20-264806 | 001-36620 | 201227233 | 34 | 29376 | ||
| 2020-10-05 | 3 | OWNERSHIP DOCUMENT | 0000921895-20-002529 | 41398 | ||||||
| 2020-10-05 | SC 13G/A | AMENDMENT NO. 1 TO THE SCHEDULE 13G | 0000921895-20-002527 | 005-88334 | 201224591 | 34 | 308482 | |||
| 2020-09-25 | D | xslFormDX01/primary_doc.xml | 06b | 0001209191-20-052086 | 021-376405 | 201199681 | 33 | 13323 | ||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0000899243-20-026300 | 19616 | ||||||
| 2020-09-24 | 3 | FORM 3 SUBMISSION | 0000899243-20-026299 | 13688 | ||||||
| 2020-09-15 | 4 | FORM 4 SUBMISSION | 0000899243-20-025172 | 6056 | ||||||
| 2020-09-15 | 4 | FORM 4 SUBMISSION | 0000899243-20-025170 | 6222 | ||||||
| 2020-09-15 | 4 | FORM 4 SUBMISSION | 0000899243-20-025169 | 6067 | ||||||
| 2020-09-15 | 4 | FORM 4 SUBMISSION | 0000899243-20-025166 | 6008 | ||||||
| 2020-09-15 | 4 | FORM 4 SUBMISSION | 0000899243-20-025165 | 6016 | ||||||
| 2020-09-15 | 3 | FORM 3 SUBMISSION | 0000899243-20-025163 | 7475 | ||||||
| 2020-09-15 | 8-K | 8-K | 1.01,2.01,3.02,5.02,5.03,7.01,9.01 | 0001193125-20-246314 | 001-36620 | 201176766 | 34 | 1759474 | ||
| 2020-09-15 | 424B3 | 424B3 | 0001564590-20-043577 | 333-237379 | 201175875 | 33 | 5968 | |||
| 2020-09-04 | 8-K | 8-K | 5.02 | 0001193125-20-240108 | 001-36620 | 201162102 | 34 | 18558 | ||
| 2020-08-18 | SC 13D/A | AMENDMENT NO. 4 | 0000947871-20-000691 | 005-88334 | 201114163 | 34 | 81350 | |||
| 2020-08-14 | 10-Q | 10-Q | 0001564590-20-040128 | 001-36620 | 201100866 | 34 | 4825555 | 1 | ||
| 2020-06-17 | 8-K | 8-K RE TURKEL COHEN DEPARTURES | 2.05,5.02 | 0001564590-20-029654 | 001-36620 | 20969771 | 34 | 39596 | ||
| 2020-05-15 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-025631 | 001-36620 | 20880525 | 34 | 205928 | ||
| 2020-05-15 | 10-Q | 10-Q | 0001564590-20-025612 | 001-36620 | 20880398 | 34 | 3908517 | 1 | ||
| 2020-05-13 | 8-K | 8-K ANNUAL MEETING RESULTS | 5.07 | 0001564590-20-025038 | 001-36620 | 20873120 | 34 | 77809 | ||
| 2020-04-23 | 8-K | 8-K | 3.01 | 0001564590-20-018029 | 001-36620 | 20809099 | 34 | 34031 | ||
| 2020-04-03 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2020-04-03 16:01:00 | 9999999995-20-000680 | 333-237379 | 20775626 | 33 | 1815 | ||
| 2020-04-02 | CORRESP | filename1.htm | 0001564590-20-014979 | 13040 | ||||||
| 2020-03-31 | UPLOAD | filename1.pdf | 0000000000-20-002791 | 39977 | ||||||
| 2020-03-31 | DEFA14A | DEFA14A | 0001564590-20-014526 | 001-36620 | 20761742 | 34 | 208098 | |||
| 2020-03-31 | DEF 14A | DEF 14A | 0001564590-20-014525 | 001-36620 | 20761736 | 34 | 1258802 | |||
| 2020-03-25 | S-8 | S-8 | 0001193125-20-085077 | 333-237380 | 20742356 | 33 | 79819 | |||
| 2020-03-25 | S-1 | S-1 | 0001193125-20-085060 | 333-237379 | 20742242 | 33 | 270087 | |||
| 2020-03-20 | 4 | FORM 4 SUBMISSION | 0000899243-20-009126 | 5723 | ||||||
| 2020-03-20 | 4 | FORM 4 SUBMISSION | 0000899243-20-009125 | 5712 | ||||||
| 2020-03-20 | 4 | FORM 4 SUBMISSION | 0000899243-20-009124 | 5758 | ||||||
| 2020-03-17 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-011277 | 001-36620 | 20719194 | 34 | 207378 | ||
| 2020-03-17 | 10-K | 10-K | 0001564590-20-011260 | 001-36620 | 20718988 | 34 | 7476351 | 1 | ||
| 2020-03-16 | PRE 14A | PRE 14A | 0001564590-20-010887 | 001-36620 | 20714393 | 34 | 1237910 | |||
| 2020-02-25 | 4 | xslF345X03/ownership.xml | 0000947871-20-000146 | 11278 | ||||||
| 2020-02-25 | 4 | xslF345X03/ownership.xml | 0000947871-20-000145 | 8608 | ||||||
| 2020-02-25 | SC 13D/A | AMENDMENT NO. 3 | 0000947871-20-000143 | 005-88334 | 20651878 | 34 | 79313 | |||
| 2020-02-20 | 8-K/A | 8-K/A | 3.02,5.03,9.01 | 0001193125-20-042564 | 001-36620 | 20632461 | 34 | 24133 | ||
| 2020-02-19 | 8-K | 8-K | 3.02,5.03,9.01 | 0001193125-20-041903 | 001-36620 | 20629781 | 34 | 120548 | ||
| 2020-02-14 | SC 13G/A | d8476089_13g-a.htm | 0000919574-20-001268 | 005-88334 | 20613012 | 34 | 143809 | |||
| 2020-02-13 | SC 13G/A | AMENDMENT NO. 1 TO THE SCHEDULE 13G | 0001013594-20-000123 | 005-88334 | 20607379 | 34 | 81226 | |||
| 2020-02-07 | 8-K | 8-K - NASDAQ DELISTING | 3.01 | 0001564590-20-003758 | 001-36620 | 20583957 | 34 | 33084 | ||
| 2020-01-27 | D | xslFormDX01/primary_doc.xml | 06b | 0001209191-20-004993 | 021-359033 | 20549934 | 33 | 13143 | ||
| 2020-01-16 | 424B3 | 424B3 | 0001193125-20-009007 | 333-232011 | 20531338 | 33 | 5187 | |||
| 2020-01-16 | 8-K | 8-K | 1.01,3.02,9.01 | 0001193125-20-008426 | 001-36620 | 20529415 | 34 | 155562 | ||
| 2020-01-14 | 424B3 | 424B3 | 0001193125-20-007238 | 333-232011 | 20526298 | 33 | 5074 | |||
| 2019-11-13 | 8-K | 8-K Q3 2019 EARNINGS RELEASE | 2.02,9.01 | 0001564590-19-043080 | 001-36620 | 191211569 | 34 | 243425 | ||
| 2019-11-13 | 10-Q | 10-Q | 0001564590-19-043039 | 001-36620 | 191211147 | 34 | 3880168 | 1 | ||
| 2019-09-30 | 4 | FORM 4 SUBMISSION | 0000899243-19-024433 | 5668 | ||||||
| 2019-09-30 | 4 | FORM 4 SUBMISSION | 0000899243-19-024432 | 5618 | ||||||
| 2019-09-30 | 4 | FORM 4 SUBMISSION | 0000899243-19-024431 | 5632 | ||||||
| 2019-08-13 | 8-K | 8-K | 2.02,9.01 | 0001564590-19-031828 | 001-36620 | 191021200 | 34 | 241389 | ||
| 2019-08-13 | 10-Q | Q2-2019 FORM 10-Q | 0001564590-19-031785 | 001-36620 | 191020661 | 34 | 3894335 | 1 | ||
| 2019-08-09 | 8-K | 8-K | 3.01 | 0001193125-19-218112 | 001-36620 | 191013959 | 34 | 18392 | ||
| 2019-07-26 | SC 13G | SCHEDULE 13G DATED JULY 16, 2019 | 0001013594-19-000483 | 005-88334 | 19977589 | 34 | 81236 | |||
| 2019-07-15 | 4 | FORM 4 SUBMISSION | 0000899243-19-019601 | 5272 | ||||||
| 2019-07-15 | 4 | FORM 4 SUBMISSION | 0000899243-19-019600 | 5264 | ||||||
| 2019-07-15 | 4 | FORM 4 SUBMISSION | 0000899243-19-019599 | 5222 | ||||||
| 2019-07-15 | 4 | FORM 4 SUBMISSION | 0000899243-19-019598 | 5312 | ||||||
| 2019-07-15 | 4 | FORM 4 SUBMISSION | 0000899243-19-019597 | 5256 | ||||||
| 2019-07-12 | 8-K | 8-K | 4.01,5.02,9.01 | 0001193125-19-193205 | 001-36620 | 19953122 | 34 | 75036 | ||
| 2019-06-28 | S-8 | S-8 | 0001193125-19-185998 | 333-232428 | 19929309 | 33 | 121910 | |||
| 2019-06-17 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2019-06-17 16:01:00 | 9999999995-19-001363 | 333-232011 | 19902570 | 33 | 1815 | ||
| 2019-06-14 | CORRESP | filename1.htm | 0001193125-19-173656 | 6891 | ||||||
| 2019-06-12 | UPLOAD | filename1.pdf | 0000000000-19-009796 | 39912 | ||||||
| 2019-06-07 | S-1 | S-1 | 0001193125-19-168171 | 333-232011 | 19885758 | 33 | 252173 | |||
| 2019-06-05 | SC 13G | d8237203_13-g.htm | 0000919574-19-003970 | 005-88334 | 19879555 | 34 | 118565 | |||
| 2019-05-22 | 4 | PRIMARY DOCUMENT | 0001562180-19-003055 | 7339 | ||||||
| 2019-05-22 | 4 | PRIMARY DOCUMENT | 0001562180-19-003052 | 7336 | ||||||
| 2019-05-22 | 4 | PRIMARY DOCUMENT | 0001562180-19-003051 | 7351 | ||||||
| 2019-05-15 | DEFA14A | DEFA14A | 0001564590-19-019437 | 001-36620 | 19828831 | 34 | 176257 | |||
| 2019-05-15 | DEF 14A | DEF 14A | 0001564590-19-019430 | 001-36620 | 19828719 | 34 | 982518 | |||
| 2019-05-14 | 8-K | 8-K | 2.02,9.01 | 0001564590-19-019162 | 001-36620 | 19823187 | 34 | 255780 | ||
| 2019-05-14 | 10-Q | 10-Q MARCH 31, 2019 | 0001564590-19-019134 | 001-36620 | 19822708 | 34 | 3416519 | 1 | ||
| 2019-05-10 | SC 13G | THE SCHEDULE 13G | 0000921895-19-001354 | 005-88334 | 19815286 | 34 | 229060 | |||
| 2019-05-10 | D | xslFormDX01/primary_doc.xml | 06b | 0001209191-19-028847 | 021-339368 | 19814779 | 33 | 13210 | ||
| 2019-05-06 | 4 | xslF345X03/ownership.xml | 0000947871-19-000337 | 13092 | ||||||
| 2019-05-06 | 4 | xslF345X03/ownership.xml | 0000947871-19-000336 | 10358 | ||||||
| 2019-05-06 | SC 13D/A | AMENDMENT NO. 2 | 0000947871-19-000328 | 005-88334 | 19800125 | 34 | 125749 | |||
| 2019-05-02 | 4 | xslF345X03/ownership.xml | 0000919574-19-003096 | 6967 | ||||||
| 2019-05-02 | 8-K | 8-K | 1.01,3.02,8.01,9.01 | 0001193125-19-135059 | 001-36620 | 19792257 | 34 | 405117 | ||
| 2019-05-01 | 424B5 | 424B5 | 0001193125-19-130755 | 333-226286 | 19784642 | 33 | 371616 | |||
| 2019-04-30 | 10-K/A | 10-K/A | 0001193125-19-129270 | 001-36620 | 19781646 | 34 | 290574 | |||
| 2019-04-22 | 8-K | 8-K CLINICAL RESULTS | 8.01,9.01 | 0001564590-19-012158 | 001-36620 | 19758664 | 34 | 76220 | ||
| 2019-04-05 | SC 13D/A | SC 13D/A | 0001104659-19-020047 | 005-88334 | 19733483 | 34 | 222521 | |||
| 2019-03-28 | 8-K | 8-K | 2.02,9.01 | 0001564590-19-009676 | 001-36620 | 19709840 | 34 | 246441 | ||
| 2019-03-28 | 10-K | 10-K | 0001564590-19-009631 | 001-36620 | 19709318 | 34 | 8289473 | 1 | ||
| 2019-03-18 | 4 | FORM 4 SUBMISSION | 0000899243-19-008141 | 8203 | ||||||
| 2019-03-18 | 4 | FORM 4 SUBMISSION | 0000899243-19-008140 | 7524 | ||||||
| 2019-03-18 | 4 | FORM 4 SUBMISSION | 0000899243-19-008139 | 5672 | ||||||
| 2019-01-08 | 8-K | 8-K CORPORATE PRESENTATION | 7.01,9.01 | 0001564590-19-000367 | 001-36620 | 19515283 | 34 | 5842250 | ||
| 2018-11-13 | 8-K | 8-K Q3 2018 EARNING RELEASE | 2.02,9.01 | 0001564590-18-029134 | 001-36620 | 181175195 | 34 | 232128 | ||
| 2018-11-13 | 10-Q | 10-Q | 0001564590-18-028982 | 001-36620 | 181174272 | 34 | 3927497 | 1 | ||
| 2018-09-13 | 4 | FORM 4 SUBMISSION | 0000899243-18-024470 | 7791 | ||||||
| 2018-09-07 | 4 | FORM 4 SUBMISSION | 0000899243-18-024043 | 5339 | ||||||
| 2018-09-07 | RW | RW | 0001193125-18-268697 | 333-226467 | 181058955 | NE | 6943 | |||
| 2018-09-04 | S-1/A | S-1/A | 0001193125-18-266270 | 333-226467 | 181052779 | 33 | 541228 | |||
| 2018-08-07 | 8-K | 8-K | 2.02,9.01 | 0001564590-18-019667 | 001-36620 | 18996385 | 34 | 227827 | ||
| 2018-08-07 | 10-Q | 10-Q | 0001564590-18-019519 | 001-36620 | 18995758 | 34 | 4249816 | 1 | ||
| 2018-08-01 | S-1 | S-1 | 0001193125-18-233511 | 333-226467 | 18982301 | 33 | 331070 | |||
| 2018-07-31 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2018-07-31 16:00:00 | 9999999995-18-001961 | 333-226286 | 18982849 | 33 | 1815 | ||
| 2018-07-31 | UPLOAD | filename1.pdf | 0000000000-18-023476 | 44842 | ||||||
| 2018-07-30 | CORRESP | filename1.htm | 0001193125-18-231910 | 6210 | ||||||
| 2018-07-23 | S-3 | S-3 | 0001193125-18-223696 | 333-226286 | 18964581 | 33 | 1089467 | |||
| 2018-06-14 | 4 | FORM 4 SUBMISSION | 0000899243-18-016655 | 5253 | ||||||
| 2018-06-14 | 4 | FORM 4 SUBMISSION | 0000899243-18-016654 | 5309 | ||||||
| 2018-06-14 | 4 | FORM 4 SUBMISSION | 0000899243-18-016653 | 5261 | ||||||
| 2018-06-14 | 4 | FORM 4 SUBMISSION | 0000899243-18-016652 | 5269 | ||||||
| 2018-06-14 | 8-K | 8-K | 5.07 | 0001564590-18-015631 | 001-36620 | 18900100 | 34 | 51335 | ||
| 2018-05-15 | SC 13D/A | SCHEDULE 13D/A - AMENDMENT NO. 3 (EXIT FILING) | 0001072613-18-000344 | 005-88334 | 18836859 | 34 | 247503 | |||
| 2018-05-11 | 8-K | 8-K FOR Q1 2018 EARNINGS RELEASE | 2.02,9.01 | 0001564590-18-013100 | 001-36620 | 18824575 | 34 | 192083 | ||
| 2018-05-11 | 10-Q | 10-Q | 0001564590-18-013090 | 001-36620 | 18824550 | 34 | 3505347 | 1 | ||
| 2018-05-02 | SC 13D/A | SCHEDULE 13D/A - AMENDMENT NO. 2 | 0001072613-18-000306 | 005-88334 | 18800677 | 34 | 244698 | |||
| 2018-04-30 | DEFA14A | DEFA14A | 0001564590-18-009751 | 001-36620 | 18788222 | 34 | 147475 | |||
| 2018-04-30 | DEF 14A | DEF 14A | 0001564590-18-009747 | 001-36620 | 18788144 | 34 | 1095124 | |||
| 2018-04-17 | SC 13D/A | SC 13D/A | 0001193125-18-119824 | 005-88334 | 18759233 | 34 | 91770 | |||
| 2018-04-02 | 8-K | 8-K Q4 2017 EARNINGS RELEASE | 2.02,9.01 | 0001564590-18-007316 | 001-36620 | 18727086 | 34 | 201948 | ||
| 2018-04-02 | 10-K | 10-K | 0001564590-18-007314 | 001-36620 | 18727081 | 34 | 8246739 | 1 | ||
| 2018-03-20 | 3 | OWNERSHIP DOCUMENT | 0000919574-18-002573 | 6068 | ||||||
| 2018-03-19 | SC 13D/A | AMENDMENT NO. 1 | 0000947871-18-000249 | 005-88334 | 18698575 | 34 | 102321 | |||
| 2018-03-15 | 4 | FORM 4 SUBMISSION | 0000899243-18-007648 | 7648 | ||||||
| 2018-03-15 | 4 | FORM 4 SUBMISSION | 0000899243-18-007647 | 7610 |
One latest value per concept from companyfacts (326 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 84.46M | 2026-11-10 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 145.17M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| ecd | NonPeoNeoAvgCompActuallyPaidAmt | NonPeoNeoAvgCompActuallyPaidAmt | USD | -290,407 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001193125-26-197732 | ||
| ecd | NonPeoNeoAvgTotalCompAmt | NonPeoNeoAvgTotalCompAmt | USD | 1.64M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001193125-26-197732 | ||
| ecd | PeoActuallyPaidCompAmt | PeoActuallyPaidCompAmt | USD | -315,000 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001193125-26-197732 | ||
| ecd | PeoTotalCompAmt | PeoTotalCompAmt | USD | 3.22M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001193125-26-197732 | ||
| ecd | TotalShareholderRtnAmt | TotalShareholderRtnAmt | USD | 66.23 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001193125-26-197732 | ||
| ffd | NetFeeAmt | NetFeeAmt | USD | 1,575.72 | 2026-09-04 | S-8 | 2026-09-04 | 0001193125-26-383824 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 1,575.72 | 2026-09-04 | S-8 | 2026-09-04 | 0001193125-26-383824 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 11.41M | 2026-09-04 | S-8 | 2026-09-04 | 0001193125-26-383824 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-09-04 | S-8 | 2026-09-04 | 0001193125-26-383824 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-04-28 | S-3 | 2026-05-01 | 0001193125-26-201426 | |||
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 2.84M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | -1,000 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | AccruedLiabilitiesAndOtherLiabilities | Accrued Liabilities and Other Liabilities | USD | 8.52M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 1.49M | 2017-06-30 | 2017 | Q2 | 10-Q | 2017-08-09 | 0001193125-17-252847 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 357,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | AccruedVacationCurrent | Accrued Vacation, Current | USD | 148,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-12 | 0001564590-21-056417 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 130,000 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | -126,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 190.49M | 2015-03-31 | 2015 | Q1 | 10-Q | 2015-05-12 | 0001193125-15-182900 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 506.63M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | AdditionalPaidInCapitalPreferredStock | Additional Paid in Capital, Preferred Stock | USD | 420.93M | 2025-03-31 | 2025 | Q1 | 10-Q/A | 2025-08-14 | 0001193125-25-180904 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 1.92M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | USD | 3.33M | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation | USD | 1.40M | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 7.28M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | AllowanceForLoanAndLeaseLossesAdjustmentsNet | Allowance for Loan and Lease Losses, Adjustments, Other | USD | 49,000 | 2015-01-01 | 2015-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 10.85M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | Assets | Assets | USD | 106.64M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 73.71M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | AssetsFairValueDisclosure | Assets, Fair Value Disclosure | USD | 531,000 | 2016-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 36,000 | 2025-12-31 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 126,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 62.92M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 62.79M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) | USD | -55,000 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-10 | 0001193125-16-499163 |
| us-gaap | BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax | Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax | USD | -11.84M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-28 | 0001564590-19-009631 |
| us-gaap | BusinessAcquisitionsProFormaNetIncomeLoss | Business Acquisition, Pro Forma Net Income (Loss) | USD | -11.79M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-28 | 0001564590-19-009631 |
| us-gaap | BusinessAcquisitionsProFormaRevenue | Business Acquisition, Pro Forma Revenue | USD | 120,000 | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 |
| us-gaap | BusinessCombinationAcquisitionRelatedCosts | Business Combination, Acquisition Related Costs | USD | 0 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-12 | 0001564590-21-056417 |
| us-gaap | BusinessExitCosts1 | Business Exit Costs | USD | 133,000 | 2015-01-01 | 2015-09-30 | 2016 | Q3 | 10-Q | 2016-11-03 | 0001193125-16-757930 |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 98,000 | 2015-01-01 | 2015-09-30 | 2016 | Q3 | 10-Q | 2016-11-03 | 0001193125-16-757930 |
| us-gaap | Cash | Cash | USD | 8.76M | 2020-06-30 | 2020 | Q2 | 10-Q | 2020-08-14 | 0001564590-20-040128 | |
| us-gaap | CashAcquiredFromAcquisition | Cash Acquired from Acquisition | USD | 11.04M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 6.88M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | CashAndCashEquivalentsPeriodIncreaseDecrease | Cash and Cash Equivalents, Period Increase (Decrease) | USD | 1.18M | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | CashCashEquivalentsAndShortTermInvestments | Cash, Cash Equivalents, and Short-term Investments | USD | 69.70M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 6.88M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -15.93M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | CashEquivalentsAtCarryingValue | Cash Equivalents, at Carrying Value | USD | 9.40M | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-05-11 | 0000950170-23-021372 | |
| us-gaap | ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | Class of Warrant or Right, Exercise Price of Warrants or Rights | USD/shares | 0.001 | 2023-12-31 | 2023 | FY | 10-K/A | 2024-08-19 | 0000950170-24-098575 | |
| us-gaap | ClassOfWarrantOrRightOutstanding | Class of Warrant or Right, Outstanding | shares | 20.96M | 2024-03-31 | 2024 | Q1 | 10-Q/A | 2024-08-19 | 0000950170-24-098582 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 450.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 81.44M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 81.44M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 82,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -74.74M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | ConversionOfStockAmountConverted1 | Conversion of Stock, Amount Converted | USD | 85.34M | 2014-01-01 | 2014-09-30 | 2014 | Q3 | 10-Q | 2014-11-13 | 0001193125-14-411225 |
| us-gaap | ConversionOfStockAmountIssued1 | Conversion of Stock, Amount Issued | USD | 4,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | ConversionOfStockSharesConverted1 | Conversion of Stock, Shares Converted | shares | 3,285 | 2020-06-01 | 2020-06-10 | 2020 | Q3 | 10-Q | 2020-11-16 | 0001564590-20-054210 |
| us-gaap | ConvertibleDebt | Convertible Debt | USD | 0 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-08 | 0001564590-17-022799 | |
| us-gaap | ConvertibleNotesPayableCurrent | Convertible Notes Payable, Current | USD | 0 | 2017-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 | |
| us-gaap | ConvertiblePreferredStockSharesIssuedUponConversion | Convertible Preferred Stock, Shares Issued upon Conversion | shares | 14.86M | 2014-09-30 | 2014 | FY | 10-K | 2015-03-26 | 0001193125-15-107051 | |
| us-gaap | CurrentIncomeTaxExpenseBenefit | Current Income Tax Expense (Benefit) | USD | 30,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | 30,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | DebtInstrumentFairValue | Debt Instrument, Fair Value Disclosure | USD | 3.40M | 2016-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 | |
| us-gaap | DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction | USD | 98,000 | 2014-01-01 | 2014-03-31 | 2015 | Q1 | 10-Q | 2015-05-12 | 0001193125-15-182900 |
| us-gaap | DebtLongtermAndShorttermCombinedAmount | Debt, Long-term and Short-term, Combined Amount | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | DeferredFederalIncomeTaxExpenseBenefit | Deferred Federal Income Tax Expense (Benefit) | USD | -2.75M | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0000950170-23-011011 |
| us-gaap | DeferredIncomeTaxExpenseBenefit | Deferred Income Tax Expense (Benefit) | USD | 5,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 7.77M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | DeferredIncomeTaxLiabilitiesNet | Deferred Income Tax Liabilities, Net | USD | 2.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 30,000 | 2013-12-31 | 2014 | FY | 10-K | 2015-03-26 | 0001193125-15-107051 | |
| us-gaap | DeferredStateAndLocalIncomeTaxExpenseBenefit | Deferred State and Local Income Tax Expense (Benefit) | USD | 5,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 68.59M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | DeferredTaxAssetsInProcessResearchAndDevelopment | Deferred Tax Assets, in Process Research and Development | USD | 28.23M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 0 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 | |
| us-gaap | DeferredTaxAssetsNetCurrent | Deferred Tax Assets, Net of Valuation Allowance, Current | USD | 414,000 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-26 | 0001193125-15-107051 | |
| us-gaap | DeferredTaxAssetsNetNoncurrent | Deferred Tax Assets, Net of Valuation Allowance, Noncurrent | USD | 32.86M | 2014-12-31 | 2014 | FY | 10-K | 2015-03-26 | 0001193125-15-107051 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 29.51M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsDomestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | USD | 27.90M | 2015-12-31 | 2015 | FY | 10-K | 2016-03-10 | 0001193125-16-499163 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal | Deferred Tax Assets, Operating Loss Carryforwards, State and Local | USD | 24.20M | 2015-12-31 | 2015 | FY | 10-K | 2016-03-10 | 0001193125-16-499163 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 44,000 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsResearch | Deferred Tax Assets, Tax Credit Carryforwards, Research | USD | 7.62M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 1.59M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals | USD | 699,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | USD | 207,000 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 63.01M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | DeferredTaxLiabilities | Deferred Tax Liabilities, Net | USD | 2.19M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | DefinedBenefitPlanContributionsByEmployer | Defined Benefit Plan, Plan Assets, Contributions by Employer | USD | 400,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | DefinedContributionPlanEmployerDiscretionaryContributionAmount | Defined Contribution Plan, Employer Discretionary Contribution Amount | USD | 19,000 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | Depreciation | Depreciation | USD | 17,000 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | DepreciationAndAmortization | Depreciation, Depletion and Amortization, Nonproduction | USD | 5,000 | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 |
| us-gaap | DilutiveSecuritiesEffectOnBasicEarningsPerShareOther | Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities | USD | 1.66B | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-12 | 0000950170-24-125622 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -0.63 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -0.69 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-12 | 0001564590-22-019921 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -0.63 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | -0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.324 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | -0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.078 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | 0.001 | 2015-01-01 | 2015-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | -0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxContingencies | Effective Income Tax Rate Reconciliation, Tax Contingency, Percent | pure | -0.039 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | -0.077 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 186,000 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | USD | 13.80M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | FairValueAdjustmentOfWarrants | Fair Value Adjustment of Warrants | USD | 11.56M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | FairValueAssetsLevel1ToLevel2TransfersAmount | Fair Value, Assets, Level 1 to Level 2 Transfers, Amount | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 | |
| us-gaap | FairValueAssetsLevel2ToLevel1TransfersAmount | Fair Value, Assets, Level 2 to Level 1 Transfers, Amount | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 | |
| us-gaap | FairValueLiabilitiesLevel1ToLevel2TransfersAmount | Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 | |
| us-gaap | FairValueLiabilitiesLevel2ToLevel1TransfersAmount | Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 | |
| us-gaap | FairValueOfAssetsAcquired | Fair Value of Assets Acquired | USD | 3.07M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-28 | 0001564590-19-009631 |
| us-gaap | GainLossOnSaleOfPropertyPlantEquipment | Gain (Loss) on Disposition of Property Plant Equipment | USD | -49,000 | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-28 | 0001564590-19-009631 |
| us-gaap | GainLossOnTerminationOfLease | Gain (Loss) on Termination of Lease | USD | 10,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | GainsLossesOnExtinguishmentOfDebt | Gain (Loss) on Extinguishment of Debt | USD | -517,000 | 2016-01-01 | 2016-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 12.53M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | Goodwill | Goodwill | USD | 0 | 2023-12-31 | 2023 | FY | 10-K/A | 2024-08-19 | 0000950170-24-098575 | |
| us-gaap | GoodwillAcquiredDuringPeriod | Goodwill, Acquired During Period | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 |
| us-gaap | GoodwillAndIntangibleAssetImpairment | Goodwill and Intangible Asset Impairment | USD | 0 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-16 | 0001564590-20-054210 |
| us-gaap | GoodwillGross | Goodwill, Gross | USD | 48.65M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 | |
| us-gaap | GoodwillImpairedAccumulatedImpairmentLoss | Goodwill, Impaired, Accumulated Impairment Loss | USD | 1.87M | 2019-12-31 | 2019 | FY | 10-K | 2020-03-17 | 0001564590-20-011260 | |
| us-gaap | GoodwillImpairmentLoss | Goodwill, Impairment Loss | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K/A | 2024-08-19 | 0000950170-24-098575 |
| us-gaap | GuaranteeObligationsCurrentCarryingValue | Guarantor Obligations, Current Carrying Value | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | ImpairmentOfLongLivedAssetsHeldForUse | Impairment of Long-Lived Assets Held-for-use | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K/A | 2025-08-14 | 0001193125-25-180865 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | -45.78M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -45.58M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | 199,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | USD | -23.21M | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-31 | 0001564590-21-016828 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 28,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeTaxExaminationPenaltiesAndInterestAccrued | Income Tax Examination, Penalties and Interest Accrued | USD | 0 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 | |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 35,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 14.75M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeTaxReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount | USD | 1.86M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-28 | 0001564590-19-009631 |
| us-gaap | IncomeTaxReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount | USD | 59,000 | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-28 | 0001564590-19-009631 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -9.57M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K/A | 2024-08-19 | 0000950170-24-098575 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 12,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 3.57M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeTaxReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | USD | 24,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | 35,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeTaxReconciliationTaxContingencies | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount | USD | 1.76M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeTaxReconciliationTaxCredits | Effective Income Tax Rate Reconciliation, Tax Credit, Amount | USD | 2.36M | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 3.51M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | -154,000 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | IncreaseDecreaseInAccountsPayableAndAccruedLiabilities | Increase (Decrease) in Accounts Payable and Accrued Liabilities | USD | 2.08M | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0000950170-23-011011 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | -246,000 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | IncreaseDecreaseInOperatingLeaseLiability | IncreaseDecreaseInOperatingLeaseLiability | USD | -265,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | IncreaseDecreaseInOtherOperatingAssets | Increase (Decrease) in Other Operating Assets | USD | 45,000 | 2015-01-01 | 2015-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 |
| us-gaap | IncreaseDecreaseInOtherOperatingLiabilities | Increase (Decrease) in Other Operating Liabilities | USD | -36,000 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 1.55M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | IncreaseDecreaseInRestrictedCash | Increase (Decrease) in Restricted Cash | USD | -150,000 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | InsuranceSettlementsReceivableCurrent | Insurance Settlements Receivable, Current | USD | 110,000 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 | |
| us-gaap | InterestAndOtherIncome | Interest and Other Income | USD | 26,000 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | InvestmentIncomeAmortizationOfPremium | Investment Income, Amortization of Premium | USD | 34,000 | 2015-01-01 | 2015-09-30 | 2015 | Q3 | 10-Q | 2015-11-10 | 0001193125-15-372762 |
| us-gaap | InvestmentsAndCash | Investments and Cash | USD | 27.40M | 2016-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 | |
| us-gaap | InvestmentsFairValueDisclosure | Investments, Fair Value Disclosure | USD | 22.94M | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 | |
| us-gaap | LeaseAndRentalExpense | Operating Leases, Rent Expense | USD | 189,000 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-12 | 0001564590-21-056417 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 395,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 294,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 293,000 | 2024-12-31 | 2024 | FY | 10-K/A | 2025-08-14 | 0001193125-25-180865 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 294,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 101,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 19,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | Liabilities | Liabilities | USD | 36.83M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 106.64M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | LiabilitiesAssumed1 | Liabilities Assumed | USD | 2.95M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-28 | 0001564590-19-009631 |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 11.70M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | LiabilitiesFairValueDisclosure | Financial and Nonfinancial Liabilities, Fair Value Disclosure | USD | 3.45M | 2016-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 | |
| us-gaap | LiabilitiesNoncurrent | Liabilities, Noncurrent | USD | 94,000 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-08 | 0001564590-17-022799 | |
| us-gaap | MarketableSecurities | Marketable Securities | USD | 0 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | -180,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | NetCashProvidedByUsedInFinancingActivitiesContinuingOperations | Net Cash Provided by (Used in) Financing Activities, Continuing Operations | USD | 7.49M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-11 | 0001564590-18-013090 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | 48.52M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | NetCashProvidedByUsedInInvestingActivitiesContinuingOperations | Net Cash Provided by (Used in) Investing Activities, Continuing Operations | USD | 23.26M | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -64.27M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Net Cash Provided by (Used in) Operating Activities, Continuing Operations | USD | -2.27M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-11 | 0001564590-18-013090 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -74.59M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersBasic | Net Income (Loss) Available to Common Stockholders, Basic | USD | -71.24M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersDiluted | Net Income (Loss) Available to Common Stockholders, Diluted | USD | -71.24M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 166,000 | 2014-01-01 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-26 | 0001193125-15-107051 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | NumberOfReportingUnits | Number of Reporting Units | Reporting_Unit | 1 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K/A | 2024-08-19 | 0000950170-24-098575 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 65.72M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -65.72M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 298,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 300,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 376,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 341,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 35,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 301,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 358,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | OperatingLeaseRightOfUseAssetAmortizationExpense | Operating Lease, Right-of-Use Asset, Amortization Expense | USD | 359,000 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K/A | 2025-08-14 | 0001193125-25-180865 |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 514,000 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-17 | 0001564590-20-011260 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 180,000 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-17 | 0001564590-20-011260 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 152,000 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-13 | 0001564590-18-028982 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 146,000 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-17 | 0001564590-20-011260 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 188,000 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-17 | 0001564590-20-011260 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | USD | 46,000 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-13 | 0001564590-18-028982 | |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.094 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 42,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | OtherAssetsCurrent | Other Assets, Current | USD | 497,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 185,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent | USD | 1,000 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | -12,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | USD | 1,000 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax | USD | -150,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 126,000 | 2016-03-31 | 2016 | Q1 | 10-Q | 2016-05-10 | 0001193125-16-584673 | |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | 2.69M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | OtherPrepaidExpenseCurrent | Other Prepaid Expense, Current | USD | 169,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | PaymentsForRestructuring | Payments for Restructuring | USD | 2.27M | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-31 | 0001564590-21-016828 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 450,000 | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0000950170-23-011011 |
| us-gaap | PaymentsRelatedToTaxWithholdingForShareBasedCompensation | Payment, Tax Withholding, Share-based Payment Arrangement | USD | 903,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | PaymentsToAcquireAvailableForSaleSecuritiesDebt | Payments to Acquire Debt Securities, Available-for-sale | USD | 68.75M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | PaymentsToAcquireMarketableSecurities | Payments to Acquire Marketable Securities | USD | 500,000 | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 9,000 | 2016-01-01 | 2016-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 |
| us-gaap | PostemploymentBenefitsLiabilityCurrent | Postemployment Benefits Liability, Current | USD | 668,000 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-28 | 0001564590-19-009631 | |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2024-12-31 | 2024 | FY | 10-K/A | 2025-08-14 | 0001193125-25-180865 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 5.00M | 2024-12-31 | 2024 | FY | 10-K/A | 2025-08-14 | 0001193125-25-180865 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 511 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-16 | 0001564590-20-054210 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 511 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-16 | 0001564590-20-054210 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 19,000 | 2016-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 4.04M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | PrepaidInsurance | Prepaid Insurance | USD | 78,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | PrepaidInterest | Prepaid Interest | USD | 544,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | ProceedsFromConvertibleDebt | Proceeds from Convertible Debt | USD | 2.93M | 2016-01-01 | 2016-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 97.93M | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 9.00M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 |
| us-gaap | ProceedsFromIssuanceOfPreferredStockAndPreferenceStock | Proceeds from Issuance of Preferred Stock and Preference Stock | USD | 95.23M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 |
| us-gaap | ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock | Proceeds from Issuance of Redeemable Convertible Preferred Stock | USD | 35.41M | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K | 2016-03-10 | 0001193125-16-499163 |
| us-gaap | ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale | USD | 117.28M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | ProceedsFromSaleAndMaturityOfMarketableSecurities | Proceeds from Sale and Maturity of Marketable Securities | USD | 4.17M | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | ProceedsFromSaleOfMachineryAndEquipment | Proceeds from Sale of Machinery and Equipment | USD | 8,000 | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-28 | 0001564590-19-009631 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 333,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | ProceedsFromWarrantExercises | Proceeds from Warrant Exercises | USD | 390,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | ProfessionalFees | Professional Fees | USD | 1.05M | 2014-01-01 | 2014-09-30 | 2014 | Q3 | 10-Q | 2014-11-13 | 0001193125-14-411225 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 228,000 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 5,000 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-31 | 0001564590-21-016828 | |
| us-gaap | PurchaseObligation | Purchase Obligation | USD | 20.70M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | RepaymentOfNotesReceivableFromRelatedParties | Repayment of Notes Receivable from Related Parties | USD | 49,000 | 2015-01-01 | 2015-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 53.19M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | RestrictedCashAndCashEquivalentsAtCarryingValue | Restricted Cash and Cash Equivalents, Current | USD | 10.10M | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-16 | 0001564590-20-054210 | |
| us-gaap | RestrictedCashAndCashEquivalentsNoncurrent | Restricted Cash and Cash Equivalents, Noncurrent | USD | 70,000 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-08 | 0001564590-17-022799 | |
| us-gaap | RestrictedCashCurrent | Restricted Cash, Current | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-28 | 0001564590-19-009631 | |
| us-gaap | RestrictedStockValueSharesIssuedNetOfTaxWithholdings | Restricted Stock, Value, Shares Issued Net of Tax Withholdings | USD | -903,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent | pure | 0.6 | 2016-07-01 | 2016-09-30 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | RestructuringCharges | Restructuring Charges | USD | 2.30M | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 |
| us-gaap | RestructuringReserve | Restructuring Reserve | USD | 12,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-31 | 0001564590-21-016828 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -475.79M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | Revenues | Revenues | USD | 0 | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 344,000 | 2022-01-01 | 2022-12-31 | 2023 | FY | 10-K/A | 2024-08-19 | 0000950170-24-098575 |
| us-gaap | SalesRevenueGoodsNet | Sales Revenue, Goods, Net (Deprecated 2018-01-31) | USD | 0 | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-03 | 0001193125-17-156191 |
| us-gaap | SeveranceCosts1 | Severance Costs | USD | 1.04M | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 2.11M | 2014-01-01 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-26 | 0001193125-15-107051 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 0.978 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | pure | 0.984 | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-12 | 0000950170-24-125622 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | pure | 0.935 | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-12 | 0000950170-24-125622 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.045 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | pure | 0.039 | 2023-01-01 | 2023-12-31 | 2024 | Q3 | 10-Q | 2024-11-12 | 0000950170-24-125622 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | pure | 0.038 | 2023-01-01 | 2023-12-31 | 2024 | Q3 | 10-Q | 2024-11-12 | 0000950170-24-125622 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 179,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 9.19M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 3.31 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 200,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period | shares | 6,710 | 2016-01-01 | 2016-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period | shares | 2.80M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price | USD/shares | 8.66 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 8,074 | 2016-01-01 | 2016-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 2.50M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 3.25 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 357,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 15.23M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 3.17 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | USD | 357,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 15.23M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | USD/shares | 3.17 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 2.3 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | USD/shares | 19.75 | 2016-01-01 | 2016-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 19.01 | 2016-01-01 | 2016-12-31 | 2017 | FY | 10-K | 2018-04-02 | 0001564590-18-007314 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 4.01 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | SharePrice | Share Price | USD/shares | 2.49 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-12 | 0000950170-24-125622 | |
| us-gaap | SharesOutstanding | Shares, Outstanding | shares | 6,204 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-12 | 0001564590-21-044038 | |
| us-gaap | ShortTermInvestments | Short-term Investments | USD | 62.79M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 30.80M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 0.056 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 |
| us-gaap | StockIssued1 | Stock Issued | USD | 598,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities | Stock Issued During Period, Shares, Conversion of Convertible Securities | shares | -3,285 | 2020-01-01 | 2020-06-30 | 2021 | Q2 | 10-Q | 2021-08-12 | 0001564590-21-044038 |
| us-gaap | StockIssuedDuringPeriodSharesReverseStockSplits | Stock Issued During Period, Shares, Reverse Stock Splits | shares | 840,115 | 2017-05-08 | 2017-05-09 | 2018 | FY | 10-K | 2019-03-28 | 0001564590-19-009631 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 100,437 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | StockIssuedDuringPeriodValueAcquisitions | Stock Issued During Period, Value, Acquisitions | USD | 1.19M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 16.68M | 2026-04-01 | 2026-06-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 8.55M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 |
| us-gaap | StockIssuedDuringPeriodValueRestrictedStockAwardGross | Stock Issued During Period, Value, Restricted Stock Award, Gross | USD | 0 | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-03 | 0001193125-17-069741 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 242,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | TangibleAssetImpairmentCharges | Tangible Asset Impairment Charges | USD | 0 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-16 | 0001564590-20-054210 |
| us-gaap | TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit | Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 |
| us-gaap | TemporaryEquityAccretionToRedemptionValueAdjustment | Temporary Equity, Accretion to Redemption Value, Adjustment | USD | 94,000 | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K | 2016-03-10 | 0001193125-16-499163 |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 164.95M | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-16 | 0001564590-20-054210 | |
| us-gaap | TemporaryEquityLiquidationPreference | Temporary Equity, Liquidation Preference | USD | 83.53M | 2013-12-31 | 2014 | FY | 10-K | 2015-03-26 | 0001193125-15-107051 | |
| us-gaap | TemporaryEquityParOrStatedValuePerShare | Temporary Equity, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | TemporaryEquitySharesAuthorized | Temporary Equity, Shares Authorized | shares | 5.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | TemporaryEquitySharesIssued | Temporary Equity, Shares Issued | shares | 339,138 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-16 | 0001564590-20-054210 | |
| us-gaap | TemporaryEquitySharesOutstanding | Temporary Equity, Shares Outstanding | shares | 339,138 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-16 | 0001564590-20-054210 | |
| us-gaap | TemporaryEquityStockIssuedDuringPeriodValueNewIssues | Temporary Equity, Stock Issued During Period, Value, New Issues | USD | 95.23M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-24 | 0001564590-22-011698 |
| us-gaap | UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic | Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | USD | 2.88M | 2024-01-01 | 2024-09-30 | 2025 | Q3 | 10-Q | 2025-11-14 | 0001193125-25-283275 |
| us-gaap | UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted | USD | 2.03M | 2024-01-01 | 2024-09-30 | 2025 | Q3 | 10-Q | 2025-11-14 | 0001193125-25-283275 |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 8.02M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions | USD | 7,000 | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-30 | 0000950170-23-011011 |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued | Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 | |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions | USD | 2.02M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions | USD | 12,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate | Unrecognized Tax Benefits that Would Impact Effective Tax Rate | USD | 0 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-13 | 0001564590-19-043039 | |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 16.60M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-19 | 0001193125-26-116164 |
| us-gaap | VariableInterestEntityActivityBetweenVIEAndEntityExpense | Variable Interest Entity, Measure of Activity, Expense | USD | 8,000 | 2014-01-01 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-26 | 0001193125-15-107051 |
| us-gaap | VariableInterestEntityOwnershipPercentage | Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage | pure | 0 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-03-10 | 0001193125-16-499163 |
| us-gaap | WarrantsAndRightsOutstanding | Warrants and Rights Outstanding | USD | 22.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 | |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 113.60M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 14.33M | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-12 | 0001564590-22-019921 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 113.60M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |
| us-gaap | WorkersCompensationLiabilityCurrent | Workers' Compensation Liability, Current | USD | 3.34M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-12 | 0001193125-26-458564 |